<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37121991</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-0407</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Amyotrophic lateral sclerosis-Motor neuron disease with a wide clinical and genetic spectrum].</ArticleTitle><Pagination><StartPage>494</StartPage><EndPage>500</EndPage><MedlinePgn>494-500</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00115-023-01479-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is the most frequent motor neuron disease. Besides a timely diagnosis, precise knowledge of the clinical manifestations and differential diagnoses is essential. While most patients develop the disease at an older age, hereditary causes play a&#xa0;more frequent role in the juvenile forms.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">What is the current state of ALS diagnostics, which new treatment options exist?</AbstractText><AbstractText Label="MATERIAL AND METHOD" NlmCategory="METHODS">Literature search using Pubmed.gov.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The main focus is on an individualized symptomatic treatment as no curative treatment approaches exist. However, new insights into the genetic and pathophysiological principles of the different forms of ALS open the way for future disease-modifying treatment options.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In cases of a clinical suspicion of ALS molecular genetic diagnostics should be considered, particularly in juvenile and young adult patients, to exclude differential diagnoses and to enable patients access to new treatment approaches.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gangfu&#xdf;</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Abteilung f&#xfc;r P&#xe4;diatrische Neurologie, Zentrum f&#xfc;r Neuromuskul&#xe4;re Erkrankungen, Zentrum f&#xfc;r Translationale Neuro- und Verhaltenswissenschaften, Universit&#xe4;t Duisburg-Essen, Essen, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohl</LastName><ForeName>Zacharias</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Spezialambulanz Bewegungsst&#xf6;rungen und Motoneuronerkrankungen, Klinik und Poliklinik f&#xfc;r Neurologie, Universit&#xe4;t Regensburg, Regensburg, Deutschland. zacharias.kohl@ukr.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Amyotrophe Lateralsklerose&#xa0;&#x2013; Motoneuronerkrankung mit gro&#xdf;em klinischem und genetischem Spektrum.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText Label="ZUSAMMENFASSUNG" NlmCategory="UNASSIGNED">HINTERGRUND: Die amyotrophe Lateralsklerose (ALS) ist die h&#xe4;ufigste Motoneuronerkrankung. Neben einer rechtzeitigen Diagnosestellung ist eine genaue Kenntnis klinischer Manifestationen und Differenzialdiagnosen erforderlich. W&#xe4;hrend die meisten Betroffenen im h&#xf6;heren Lebensalter erkranken, spielen bei den juvenilen Formen h&#xe4;ufig erbliche Ursachen eine Rolle.</AbstractText><AbstractText Label="FRAGESTELLUNG" NlmCategory="UNASSIGNED">Wie ist der aktuelle Stand der ALS-Diagnostik, welche bekannten und welche neuen Therapieoptionen gibt es?</AbstractText><AbstractText Label="MATERIAL UND METHODE" NlmCategory="UNASSIGNED">Literaturrecherche mittels Pubmed.gov.</AbstractText><AbstractText Label="ERGEBNISSE" NlmCategory="UNASSIGNED">Bisher steht die individuelle symptomatische Behandlung im Vordergrund, da keine kurativen Therapieans&#xe4;tze existieren. Allerdings er&#xf6;ffnen neue Erkenntnisse &#xfc;ber genetische und pathophysiologische Grundlagen der verschiedenen Formen der ALS zuk&#xfc;nftige krankheitsmodifizierende Therapieoptionen.</AbstractText><AbstractText Label="SCHLUSSFOLGERUNGEN" NlmCategory="UNASSIGNED">Beim klinischem Verdacht auf eine ALS sollte eine molekulargenetische Diagnostik erwogen werden, um Differenzialdiagnosen abzukl&#xe4;ren und den Patienten den Zugang zu neuen Therapieans&#xe4;tzen zu erm&#xf6;glichen.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease-modifying treatment</Keyword><Keyword MajorTopicYN="N">Molecular genetic diagnostics</Keyword><Keyword MajorTopicYN="N">Pathophysiology</Keyword><Keyword MajorTopicYN="N">Protein homeostasis</Keyword><Keyword MajorTopicYN="N">Tofersen</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>30</Day><Hour>23</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37121991</ArticleId><ArticleId IdType="doi">10.1007/s00115-023-01479-3</ArticleId><ArticleId IdType="pii">10.1007/s00115-023-01479-3</ArticleId></ArticleIdList><ReferenceList><Title>Literatur</Title><Reference><Citation>Andrews&#xa0;JA, Jackson&#xa0;CE, Heiman-Patterson&#xa0;TD et al (2020) Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 21(7&#x2013;8):509&#x2013;518</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust&#xa0;E, Boentert&#xa0;M, Brenner&#xa0;D et&#xa0;al (2022) Amyotrophe Lateralsklerose und andere Motoneuronerkrankungen. Pathophysiologie, Diagnostik und Therapie, 1.&#xa0;Aufl. Kohlhammer, Stuttgart</Citation></Reference><Reference><Citation>Beeldman&#xa0;E, Raaphorst&#xa0;J, Klein Twennaar&#xa0;M et al (2016) The cognitive profile of ALS: a&#xa0;systematic review and meta-analysis update. J&#xa0;Neurol Neurosurg Psychiatry 87(6):611&#x2013;619</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310734</ArticleId><ArticleId IdType="pubmed">26283685</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider&#xa0;J, Del Tredici&#xa0;K, Toledo&#xa0;JB et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74(1):20&#x2013;38</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId><ArticleId IdType="pmc">3785076</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks&#xa0;BR, Miller&#xa0;RG, Swash&#xa0;M et&#xa0;al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293&#x2013;299</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggermann&#xa0;K, Gess&#xa0;B, H&#xe4;usler&#xa0;M et&#xa0;al (2018) Hereditary neuropathies. Dtsch Arztebl Int 115(6):91&#x2013;97</Citation><ArticleIdList><ArticleId IdType="pubmed">29478438</ArticleId><ArticleId IdType="pmc">5832893</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg&#xa0;E, Oeckl&#xa0;P, Steinacker&#xa0;P et&#xa0;al (2018) Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 90(1):e22&#x2013;e30</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004761</ArticleId><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi&#xa0;D, Meneri&#xa0;M, Saccomanno&#xa0;D et&#xa0;al (2019) Diagnostic and prognostic role of blood and cerebrospinal fluid and blood neurofilaments in amyotrophic lateral sclerosis: a review of the literature. Int J Mol Sci 20(17):4152. https://doi.org/10.3390/ijms20174152</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20174152</ArticleId><ArticleId IdType="pubmed">31450699</ArticleId><ArticleId IdType="pmc">6747516</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman&#xa0;O, Al-Chalabi&#xa0;A, Chio&#xa0;A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17071</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson&#xa0;JO, Chia&#xa0;R, Miller&#xa0;DE et&#xa0;al (2021) Association of variants in the SPTLC1 gene with juvenile amyotrophic lateral sclerosis. JAMA Neurol 78(10):1236&#x2013;1248</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.2598</ArticleId><ArticleId IdType="pubmed">34459874</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehky&#xa0;T, Grunseich&#xa0;C (2021) Juvenile amyotrophic lateral sclerosis: a review. Genes 12(12):1935</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12121935</ArticleId><ArticleId IdType="pubmed">34946884</ArticleId><ArticleId IdType="pmc">8701111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Petri S, Gro&#xdf;kreutz J (2021) Motoneuronerkrankungen. S1-Leitlinie. In: Deutsche Gesellschaft f&#xfc;r Neurologie (Hrsg) Leitlinien f&#xfc;r Diagnostik und Therapie in der Neurologie</Citation></Reference><Reference><Citation>Marin&#xa0;B, Boum&#xe9;diene&#xa0;F, Logroscino&#xa0;G et al (2017) Variation in worldwide incidence of amyotrophic lateral sclerosis: a&#xa0;meta-analysis. Int J Epidemiol 46(1):57&#x2013;74</Citation><ArticleIdList><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, USA Online Mendelian inheritance in man, OMIM&#xae;. https://omim.org/ . Zugegriffen: 29. Nov. 2022</Citation></Reference><Reference><Citation>McShane&#xa0;MA, Boyd&#xa0;S, Harding&#xa0;B et al (1992) Progressive bulbar paralysis of childhood. A reappraisal of Fazio-Londe disease. Brain 115(6):1889&#x2013;1900</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/115.6.1889</ArticleId><ArticleId IdType="pubmed">1486466</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead&#xa0;RJ, Shan&#xa0;N, Reiser&#xa0;HJ et&#xa0;al (2022) Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov 22:185&#x2013;212</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00612-2</ArticleId><ArticleId IdType="pubmed">36543887</ArticleId><ArticleId IdType="pmc">9768794</ArticleId></ArticleIdList></Reference><Reference><Citation>Mgarban&#xa0;A, Desguerres&#xa0;I, Rizkallah&#xa0;E et al (2000) Brown-Vialetto-Van Laere syndrome in a&#xa0;large inbred Lebanese family: confirmation of autosomal recessive inheritance? Am J Med Genet 92(2):117&#x2013;121</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-8628(20000515)92:2&lt;117::AID-AJMG7&gt;3.0.CO;2-C</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohassel&#xa0;P, Donkervoort&#xa0;S, Lone&#xa0;MA et&#xa0;al (2021) Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat Med 27(7):1197&#x2013;1204</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01346-1</ArticleId><ArticleId IdType="pubmed">34059824</ArticleId><ArticleId IdType="pmc">9309980</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller&#xa0;K, Brenner&#xa0;D, Weydt&#xa0;P et&#xa0;al (2018) Comprehensive analysis of the mutation spectrum in 301 German ALS families. J&#xa0;Neurol Neurosurg Psychiatry 89(8):817&#x2013;827</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317611</ArticleId><ArticleId IdType="pubmed">29650794</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani&#xa0;R, Larson&#xa0;TC, Wagner&#xa0;L et&#xa0;al (2022) Survival and epidemiology of amyotrophic lateral sclerosis (ALS) cases in the Chicago and Detroit metropolitan cohort: incident cases 2009&#x2013;2011 and survival through 2018. Amyotroph Lateral Scler Frontotemporal Degener. https://doi.org/10.1080/21678421.2022.2121167</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2022.2121167</ArticleId><ArticleId IdType="pubmed">36200180</ArticleId><ArticleId IdType="pmc">9568617</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan&#xa0;R, Haque&#xa0;S, Coley&#xa0;K et al (2020) Multifaceted genes in amyotrophic lateral sclerosis-frontotemporal dementia. Front Neurosci 14:684</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00684</ArticleId><ArticleId IdType="pubmed">32733193</ArticleId><ArticleId IdType="pmc">7358438</ArticleId></ArticleIdList></Reference><Reference><Citation>Regensburger&#xa0;M, Weidner&#xa0;N, Kohl&#xa0;Z (2018) Motoneuronerkrankungen : Klinische und genetische Differenzialdiagnostik. Nervenarzt 89(6):658&#x2013;665</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00115-018-0524-2</ArticleId><ArticleId IdType="pubmed">29767817</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm&#xa0;A, Peter&#xa0;RS, Erhardt&#xa0;S et&#xa0;al (2017) Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J&#xa0;Neurol 264(4):749&#x2013;757</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8413-3</ArticleId><ArticleId IdType="pubmed">28220290</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauter&#xa0;S, Neesen&#xa0;J, Paulus&#xa0;W et al (2002) Heredit&#xe4;re spastische Paraplegie. Dtsch Arztebl 99(7):A-434</Citation></Reference><Reference><Citation>Shefner&#xa0;JM, Al-Chalabi&#xa0;A, Baker&#xa0;MR et al (2020) A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 131(8):1975&#x2013;1978</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner&#xa0;MR, Barohn&#xa0;RJ, Corcia&#xa0;P et&#xa0;al (2020) Primary lateral sclerosis: consensus diagnostic criteria. J&#xa0;Neurol Neurosurg Psychiatry 91(4):373&#x2013;377</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322541</ArticleId><ArticleId IdType="pubmed">32029539</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen&#xa0;W, van der Spek&#xa0;RAA, Bakker&#xa0;MK et al (2021) Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet 53(12):1636&#x2013;1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId><ArticleId IdType="pmc">8648564</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel&#xa0;S, Ludolph&#xa0;AC (2019) Amyotrophe Lateralsklerose &#x2013; ein Update zu Diagnostik, Therapie und Forschung. Neurologie up2date 2(02):191&#x2013;209</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-0865-3953</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel&#xa0;S, Maier&#xa0;A, Steinbach&#xa0;R et al (2022) Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol 79(2):121&#x2013;130</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.4893</ArticleId><ArticleId IdType="pubmed">35006266</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>